Objective: To investigate safety and effectiveness of NOMAC-E2 and levonorgestrel-containing COCs (COC) in users over 40.
Methods: In this large, observational study, new users of NOMAC-E2 and COC were recruited in Europe, Australia, and Latin America and followed-up questionnaires. Incidence of venous thromboembolism (VTE) was expressed as incidence rate (IR; events/10 women-years [WY]). Unintended pregnancy was expressed by the Pearl Index (PI; contraceptive failures/100 WY). Mood and weight changes were defined as mean changes in mood score and percentage of body weight.
Results: Overall, 7,762 NOMAC-E2 and 6,059 COC users over 40 were followed-up. NOMAC-E2 showed no increased VTE risk compared to COC; confirmed events: 5 NOMAC-E2 (IR 5.9; 95% CI, 1.9-13.7) vs 4 COC (IR 5.9; 95% CI, 1.6-15.1). Unintended pregnancy did not differ substantially between cohorts; confirmed events: 4 NOMAC-E2 (PI 0.05; 95% CI, 0.01-0.13) vs 5 COC (PI 0.08; 95% CI, 0.03-0.18). No differential effect on mood and weight was observed between cohorts.
Conclusions: NOMAC-E2 can be considered a valid alternative to COC in perimenopausal women.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09513590.2023.2166032 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A review of the pharmacology, clinical outcomes, and real-world effectiveness, safety, and non-contraceptive effects of NOMAC/E2.
Eur J Obstet Gynecol Reprod Biol X
March 2024
Theramex HQ UK Ltd, 50 Broadway, 5th Floor, London SW1H 0BL, UK.
Article Synopsis
- * Nomegestrol acetate + 17β-estradiol (NOMAC/E2) is a combined oral contraceptive that effectively inhibits ovulation and has unique characteristics, as outlined in clinical and real-world studies.
- * The review discusses NOMAC/E2's pharmacological effects, clinical efficacy, safety data, and non-contraceptive benefits, finding it has a long half-life, effective pregnancy prevention, and low risk for serious safety issues like venous thromboembolism.
Is the multinational, surveillance PRO-E2 study informative for all countries? The Italian data on VTE and contraceptive effectiveness.
Eur J Contracept Reprod Health Care
February 2024
Full Professor Retired, University of Florence, Florence, Italy.
Purpose: To evaluate whether the thromboembolic risk and contraceptive effectiveness of NOMAC-E2 observed in the PRO-E2 study can be extended to each participating country, as lifestyle, cardiovascular risk factors and prescribing habits may differ geographically. This analysis was performed on the PRO-E2 Italian subpopulation, where smoking habit and women over 35 years were more prevalent compared with the overall study population.
Materials And Methods: Data from NOMAC-E2 or levonorgestrel-containing COCs (COC) new users were descriptively analysed.
Objective: To investigate safety and effectiveness of NOMAC-E2 and levonorgestrel-containing COCs (COC) in users over 40.
Methods: In this large, observational study, new users of NOMAC-E2 and COC were recruited in Europe, Australia, and Latin America and followed-up questionnaires. Incidence of venous thromboembolism (VTE) was expressed as incidence rate (IR; events/10 women-years [WY]).
NOMAC-E2 shows a better contraceptive effectiveness than LNG combined oral contraceptives in women under 25: real-world PRO-E2 study.
Gynecol Endocrinol
December 2023
Berlin Center for Epidemiology and Health Research (ZEG), Berlin, Germany.
To investigate unintended pregnancy and changes in mood, acne, and weight in NOMAC-E2 vs levonorgestrel-containing COC (COC) users under 25 years. In this large, observational study, new users (first-ever users of an eligible COC or restarting with the same or a new eligible COC after a break of at least 2 months) of NOMAC-E2 and COC were recruited in 12 countries in Europe, Australia, and Latin America and followed up questionnaires for up to 2 years. Unintended pregnancy was expressed by the Pearl Index (PI; contraceptive failures/100 women-years).
View Article and Find Full Text PDFUnintended pregnancy in users of nomegestrol acetate and 17β-oestradiol (NOMAC-E2) compared with levonorgestrel-containing combined oral contraceptives: final results from the PRO-E2 study.
Eur J Contracept Reprod Health Care
December 2021
Berlin Center for Epidemiology and Health Research (ZEG), Berlin, Germany.
Objective: To assess and compare the risk of unintended pregnancy in NOMAC-E2 users with levonorgestrel-containing COC (COC) users in clinical practice.
Study Design: In this observational study, new users of NOMAC-E2 and COC were recruited in Europe, Australia, and Latin America and followed for up to 2 years. Unintended pregnancy was expressed by the Pearl Index (contraceptive failures per 100 women-years [WY]), crude hazard ratios (HR) and adjusted hazard ratios (HR).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!